BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 24962722)

  • 1. Intranasal formulations: promising strategy to deliver vaccines.
    Riese P; Sakthivel P; Trittel S; Guzmán CA
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1619-34. PubMed ID: 24962722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response.
    Zaman M; Simerska P; Toth I
    Curr Drug Deliv; 2010 Apr; 7(2):118-24. PubMed ID: 20158484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chitosan-based delivery systems for mucosal vaccines.
    Jabbal-Gill I; Watts P; Smith A
    Expert Opin Drug Deliv; 2012 Sep; 9(9):1051-67. PubMed ID: 22708875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New strategies for using mucosal vaccination to achieve more effective immunization.
    Walker RI
    Vaccine; 1994 Apr; 12(5):387-400. PubMed ID: 8023545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
    Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
    Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?
    Marasini N; Kaminskas LM
    Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal vaccine innovation.
    Jabbal-Gill I
    J Drug Target; 2010 Dec; 18(10):771-86. PubMed ID: 21047271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal delivery of nanoparticle-based vaccines.
    Marasini N; Skwarczynski M; Toth I
    Ther Deliv; 2017 Jan; 8(3):151-167. PubMed ID: 28145824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of nasal vaccines.
    Slütter B; Hagenaars N; Jiskoot W
    J Drug Target; 2008 Jan; 16(1):1-17. PubMed ID: 18172815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel vaccine development strategies for inducing mucosal immunity.
    Fujkuyama Y; Tokuhara D; Kataoka K; Gilbert RS; McGhee JR; Yuki Y; Kiyono H; Fujihashi K
    Expert Rev Vaccines; 2012 Mar; 11(3):367-79. PubMed ID: 22380827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid-in-oil nanodispersions for intranasal vaccination: Enhancement of mucosal and systemic immune responses.
    Kong Q; Kitaoka M; Tahara Y; Wakabayashi R; Kamiya N; Goto M
    Int J Pharm; 2019 Dec; 572():118777. PubMed ID: 31678377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
    Li R; Lim A; Alonso S
    Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal route for vaccine and drug delivery: Features and current opportunities.
    Lobaina Mato Y
    Int J Pharm; 2019 Dec; 572():118813. PubMed ID: 31678521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnology solutions for mucosal immunization.
    Chadwick S; Kriegel C; Amiji M
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):394-407. PubMed ID: 19931581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticles for nasal vaccination.
    Csaba N; Garcia-Fuentes M; Alonso MJ
    Adv Drug Deliv Rev; 2009 Feb; 61(2):140-57. PubMed ID: 19121350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
    Wang SH; Thompson AL; Hickey AJ; Staats HF
    Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal immunisation: adjuvants and delivery systems.
    Moyle PM; McGeary RP; Blanchfield JT; Toth I
    Curr Drug Deliv; 2004 Oct; 1(4):385-96. PubMed ID: 16305400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.